利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.055 秒)

    Inhibitors of bruton's tyrosine kinase
    43.
    发明申请
    Inhibitors of bruton's tyrosine kinase 有权
    布鲁特酪氨酸激酶抑制剂

    公开(公告)号：US20100016301A1

    公开(公告)日：2010-01-21

    申请号：US12460226

    申请日：2009-07-15

    申请人： Nolan James Dewdney ,  Yan Lou ,  Eric Brian Sjogren ,  Michael Soth

    发明人： Nolan James Dewdney ,  Yan Lou ,  Eric Brian Sjogren ,  Michael Soth

    IPC分类号： A61K31/5377 ,  C07D487/04 ,  A61K31/437 ,  C07D471/04

    CPC分类号： C07D487/04 ,  C07D471/04

    摘要： This application discloses 6-Phenyl-imidazo[1,2-a]pyridine and 6-Phenyl-imidazo[1,2-b]pyridazine derivatives according to generic Formulae I-V: wherein, variables Q, R, X, Y1, Y2, Y3, Y4, n, and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-V and at least one carrier, diluent or excipient.

    摘要翻译： 本申请公开了根据通式IV的6-苯基 - 咪唑并[1,2-a]吡啶和6-苯基 - 咪唑并[1,2-b]哒嗪衍生物：其中，变量Q，R，X，Y 1， Y3，Y4，n和m如本文所述限定Btk。 本文公开的化合物可用于调节Btk的活性并治疗与过量Btk活性相关的疾病。 该化合物还可用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，例如类风湿性关节炎。 还公开了包含式I-V化合物和至少一种载体，稀释剂或赋形剂的组合物。

    Inhibitors of bruton's tyrosine kinase
    44.
    发明申请
    Inhibitors of bruton's tyrosine kinase 有权
    布鲁特酪氨酸激酶抑制剂

    公开(公告)号：US20090186898A1

    公开(公告)日：2009-07-23

    申请号：US12316343

    申请日：2008-12-11

    申请人： Nolan James Dewdney ,  Yan Lou ,  Michael Soth

    发明人： Nolan James Dewdney ,  Yan Lou ,  Michael Soth

    IPC分类号： A61K31/5025 ,  C07D487/04 ,  A61P29/00 ,  A61P19/02

    CPC分类号： A61K31/5025 ,  C07D487/04

    摘要： This application discloses novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives according to Formulae I-VI: wherein R, R′, R″, Q, X, and Y are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-VI and at least one carrier, diluent or excipient.

    摘要翻译： 本申请公开了根据式I-VI的新的咪唑并[1,2-a]吡啶和咪唑并[1,2-b]哒嗪衍生物：其中R，R'，R“，Q，X和Y定义为 这抑制Btk。 本文公开的化合物可用于调节Btk的活性并治疗与过量Btk活性相关的疾病。 该化合物还可用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，例如类风湿性关节炎。 还公开了含有式I-VI化合物和至少一种载体，稀释剂或赋形剂的组合物。

    Inhibitors of bruton's tyrosine kinase
    47.
    发明授权
    Inhibitors of bruton's tyrosine kinase 有权
    布鲁特酪氨酸激酶抑制剂

    公开(公告)号：US08618098B2

    公开(公告)日：2013-12-31

    申请号：US13358557

    申请日：2012-01-26

    申请人： Nolan James Dewdney ,  Rama K. Kondru ,  Bradley E. Loe ,  Yan Lou ,  Joel McIntosh ,  Timothy D. Owens ,  Michael Soth

    发明人： Nolan James Dewdney ,  Rama K. Kondru ,  Bradley E. Loe ,  Yan Lou ,  Joel McIntosh ,  Timothy D. Owens ,  Michael Soth

    IPC分类号： A61K31/5377 ,  A61K31/517

    CPC分类号： C07D417/14 ,  C07D401/10 ,  C07D401/14 ,  C07D413/14

    摘要： This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: wherein, variables R, X, Y1, Y2, Y2′, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-IV and at least one carrier, diluent or excipient.

    摘要翻译： 本申请公开了根据通式I-IV的5-苯基-1H-吡啶-2-酮和6-苯基-2H-哒嗪-3-酮衍生物：其中，变量R，X，Y 1，Y 2，Y 2'，Y 3 ，Y4，n和m定义如本文所述，其抑制Btk。 本文公开的化合物可用于调节Btk的活性并治疗与过量Btk活性相关的疾病。 该化合物还可用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，例如类风湿性关节炎。 还公开了包含式I-IV化合物和至少一种载体，稀释剂或赋形剂的组合物。